Remove Contract Manufacturing Remove Drugs Remove Pharmacy
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. Prices would be “a fraction of the $300 per vial prices charged by insulin manufacturers.”.

Insulin 328
article thumbnail

Catching up with LGM Pharma ahead of CPhI North America to find out about its pipeline

Outsourcing Pharma

LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enzalutamide by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Hormones 113
article thumbnail

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-06835375?

Pharmaceutical Technology

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

article thumbnail

Enzalutamide by Pfizer for Myelofibrosis: Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Myelofibrosis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Hormones 100
article thumbnail

Enzalutamide by Pfizer for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase I drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Hormones 100
article thumbnail

What to Look for in a Pharmaceutical Packaging Company

Pharma Packaging Solutions

Here are a few things to consider when selecting a pharmaceutical contract manufacturing company. A pharmaceutical contract manufacturing company can provide a lot more than just packaging. Want to know more about what sets Tjoapack US apart from other pharmaceutical contract manufacturing companies ?